Kllotas

Dutasteride/Tamsulosin, the active ingredients in Kllotas, are a 5-alpha-reductase inhibitor and an alpha-1 adrenergic blocker presented as an oral tablet for oral use. The combination is indicated for the treatment of benign prostatic hyperplasia in adult men, helping to improve urinary flow and reduce prostate size.

GNH USA supplies Kllotas as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for each batch. Global logistics are coordinated to ensure timely delivery across diverse markets.

Kllotas acts on the hormonal and smooth-muscle pathways that contribute to benign prostatic hyperplasia.

Benign prostatic hyperplasia (BPH): reduces prostate volume and alleviates urinary symptoms such as frequency and urgency. Lower urinary tract symptoms (LUTS) due to BPH: improves urinary flow rate and decreases nocturia. Prostate enlargement in adult men: helps to prevent disease progression and the need for surgical intervention.

Kllotas may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Erectile dysfunction: reduced ability to achieve or maintain an erection. - Decreased libido: lowered sexual desire. - Dizziness: sensation of light‑headedness, especially after standing. - Ejaculatory disorder: reduced volume or painful ejaculation.

Serious or Rare Side Effects: - Orthostatic hypotension: marked drop in blood pressure upon standing, leading to fainting. - Priapism: prolonged, painful erection requiring emergency care. - Severe allergic reaction: rash, swelling, or difficulty breathing.

Before initiating therapy, clinicians should consider several safety aspects.

Monitor prostate-specific antigen (PSA) levels: Dutasteride can lower PSA, potentially masking cancer detection. Assess cardiovascular status: Tamsulosin may cause hypotension; caution in patients with heart disease. Avoid use in women of childbearing potential: drug may cause fetal harm. Review concomitant medications: potential interactions with CYP3A4 inhibitors. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Kllotas can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase dutasteride exposure. - Alpha‑blocker combinations (e.g., doxazosin, terazosin): risk of additive hypotension. - Warfarin: tamsulosin may enhance anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., metoprolol): tamsulosin may affect metabolism. - Antihypertensive agents (e.g., ACE inhibitors): may require dose adjustment. - Rifampin: may reduce dutasteride levels.